St. Jude Children's Research Hospital
Developing genome editing technologies as safe and effective therapies for human genetic conditions such as sickle cell disease.
In the Tsai lab, our long-term goal is to advance safe and effective genome editing technologies to treat hematological conditions from bench to the bedside. Our current projects include:
Protein engineering of CRISPR-Cas genome editors with improved activity, specificity, and precise control of DNA repair outcomes.
Understanding safety of genome editors, including defining their genome-wide activities and interpreting the biological consequences.
Advancing autologous genome edited hematopoietic stem cells for treatment of patients with sickle cell disease to a clinical trial at St. Jude.
We are grateful for support from the NIH Common Fund Somatic Cell Genome Editing Consortium, the Doris Duke Charitable Foundation, and St. Jude/ALSAC.
Tsai lab and co-investigators awarded NIH Somatic Cell Genome Editing Consortium grants to optimize CHANGE-seq, GUIDE-seq, and gRNA sequencing for use in development of genome editing medicines.
Shengdar promoted to Associate Member.
Rachael starts in the lab as a lead researcher.
Elizabeth starts in the lab as a researcher.
Andrea awarded NIH F31 pre-doctoral fellowship.
Tsai and Weiss labs awarded renewal of DDCF funded grant to advance SCD genome editing therapy.
Abby joins the lab as a research technologist.
Kasey awarded Diggs postdoctoral fellowship
Michelle, Kiera, and Tiffany join the lab as research technologists.
Andrea joins the lab as a graduate student.
Kasey joins the lab as a post-doctoral fellow.
Varun joins the lab as a senior research technologist.